Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by S Chiva-Razavi
Cost-Effectiveness Analysis of Secukinumab in Ankylosing Spondylitis: A Canadian Perspective
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Applying the Institute for Clinical and Economic Review’s (ICER) Methodology to Canada: An Improved Way to Take Into Consideration Drug Affordability Challenges?
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Pms31 - Secukinumab as a More Eeficient Alternative for Ankylosing Spondylitis Treatment: A Cost Per Responder Analysis From Korean Perspective
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Correction To: Secukinumab: A Review in Ankylosing Spondylitis
Drugs
Pharmacology
Pms29 - Secukinumab Versus Adalimumab in the Treatment of Ankylosing Spondylitis: A Cost Per Responder Analysis Among 52 Weeks From a Tunisian Perspective.
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pms42 - Secukinumab Versus Adalimumab for the Treatment of Ankylosing Spondylitis: A 52-Week Cost Per Responder Analysis From the Portuguese Payer Perspective
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
The Advent of IL-17A Blockade in Ankylosing Spondylitis: Secukinumab, Ixekizumab and Beyond
Expert Review of Clinical Immunology
Allergy
Immunology
Pms20 - Budget Impact of Introducing Secukinumab in the Treatment of Ankylosing Spondylitis From the Private Payer Perspective in Brazil
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Assessment of Cost-Effectiveness Models for Biologics in the Management of Severe Ankylosing Spondylitis
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Real-World Data on Secukinumab Use for Psoriatic Arthritis and Ankylosing Spondylitis
Therapeutic Advances in Musculoskeletal Disease
Rheumatology
Orthopedics
Sports Medicine
Cost-Utility Analysis of Secukinumab Use Versus TNF-Α Inhibitors, in Patients With Ankylosing Spondilytis
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
